Download PDF
Kardiologie up2date 2009; 5(3): 213-218
DOI: 10.1055/s-0029-1215078
Koronare Herzerkrankung und Atherosklerose

© Georg Thieme Verlag KG Stuttgart · New York

Neue Biomarker im akuten Koronarsyndrom

Tanja  K.  Rudolph, Volker  Rudolph, Stephan  Baldus
Further Information

Publication History

Publication Date:
15 October 2009 (online)

Also available at
    Permissions and Reprints All articles of this category

Abstract

Patients presenting with acute coronary syndromes still represent a high risk population in whom early risk assessment is of essential importance to guide therapy. Besides clinical symptoms and ECG criteria cardiac biomarkers have emerged as critical tools for risk stratification. Whereas troponins remain the most validated biomarkers used in clinical practice today, current research aims to identify novel markers which are capable of indentifying patients at risk at an earlier stage of the disease, that ist prior to myocardial damage.

Literatur

  • 1 Antman E M, Sacks D B, Rifai N. et al . Time to positivity of a rapid bedside assay for cardiac-specific troponin T predicts prognosis in acute coronary syndromes: a Thrombolysis in Myocardial Infarction (TIMI) 11A substudy.  J Am Coll Cardiol. 1998;  31 326-330
    PubMedGoogle Scholar
  • 2 Hartmann F, Giannitsis E, Kurowski V. et al . Risk stratification and therapeutic decision making in patients with acute coronary syndrome – the role of cardiac troponin T.  Clin Chem Lab Med. 1999;  37 1107-1111
    CrossrefPubMedGoogle Scholar
  • 3 Heeschen C, Hamm C W, Goldmann B. et al . Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban. PRISM Study Investigators. Platelet Receptor Inhibition in Ischemic Syndrome Management.  Lancet. 1999;  354 1757-1762
    CrossrefPubMedGoogle Scholar
  • 4 Bigger J T, Heller C A, Wenger T L, Weld F M. Risk stratification after acute myocardial infarction.  Am J Cardiol. 1978;  42 202
    CrossrefPubMedGoogle Scholar
  • 5 Störk T V, Wu A H, Müller-Bardorff M. et al . Diagnostic and prognostic role of myoglobin in patients with suspected acute coronary syndrome. North-Württemberg Infarction Study (NOWIS) Group.  Am J Cardiol. 2000;  86 1371-1374, A5
    CrossrefPubMedGoogle Scholar
  • 6 Ohman E M, Casey C, Bengtson J R. et al . Early detection of acute myocardial infarction: additional diagnostic information from serum concentrations of myoglobin in patients without ST elevation.  Br Heart J. 1990;  63 335-338
    CrossrefPubMedGoogle Scholar
  • 7 Heeschen C, Hamm C W, Mitrovic V. et al . Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Investigators. N-terminal pro-B-type natriuretic peptide levels for dynamic risk stratification of patients with acute coronary syndromes.  Circulation. 2004;  110 3206-3212
    CrossrefPubMedGoogle Scholar
  • 8 Jernberg T, Stridsberg M, Venge P, Lindahl B. N-terminal pro brain natriuretic peptide on admission for early risk stratification of patients with chest pain and no ST-segment elevation.  J Am Coll Cardiol. 2002;  40 437-445
    CrossrefPubMedGoogle Scholar
  • 9 Fox K A, Dabbous O H, Goldberg R J. et al . Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE).  BMJ. 2006;  333 1091
    CrossrefPubMedGoogle Scholar
  • 10 Jassim Al Suwaidi M B, Reddan D N. et al . Prognostic Implications of Abnormalities in Renal Function in Patients With Acute Coronary Syndromes.  Circulation. 2002;  106 974-980
    CrossrefPubMedGoogle Scholar
  • 11 Jernberg T, Lindahl B, James S. et al . Cystatin C: a novel predictor of outcome in suspected or confirmed non-ST-elevation acute coronary syndrome.  Circulation. 2004;  110 2342-2348
    CrossrefPubMedGoogle Scholar
  • 12 Kilic T, Oner G, Ural E. et al . Comparison of the long-term prognostic value of Cystatin C to other indicators of renal function, markers of inflammation and systolic dysfunction among patients with acute coronary syndrome.  Atherosclerosis. 2009;  Epup ahead of print
    PubMedGoogle Scholar
  • 13 Windhausen F, Hirsch A, Fischer J. et al . Cystatin C for enhancement of risk stratification in non-ST elevation acute coronary syndrome patients with an increased troponin T.  Clin Chem. 2009;  55 1118-1125
    CrossrefPubMedGoogle Scholar
  • 14 Mueller C, Buettner H J, Hodgson J M. et al . Inflammation and long-term mortality after non-ST elevation acute coronary syndrome treated with a very early invasive strategy in 1042 consecutive patients.  Circulation. 2002;  105 1412-1415
    CrossrefPubMedGoogle Scholar
  • 15 Sabatine M S, Morrow D A, Giugliano R P. et al . Association of hemoglobin levels with clinical outcomes in acute coronary syndromes.  Circulation. 2005;  111 2042-2049
    CrossrefPubMedGoogle Scholar
  • 16 Giraldez R R, Sabatine M S, Morrow D A. et al . Baseline hemoglobin concentration and creatinine clearance composite laboratory index improves risk stratification in ST-elevation myocardial infarction.  Am Heart J. 2009;  157 517-524
    CrossrefPubMedGoogle Scholar
  • 17 Libby P, Theroux P. Pathophysiology of coronary artery disease.  Circulation. 2005;  111 3481-3488
    CrossrefPubMedGoogle Scholar
  • 18 Packard R R, Libby P. Inflammation in atherosclerosis: from vascular biology to biomarker discovery and risk prediction.  Clin Chem. 2008;  54 24-38
    PubMedGoogle Scholar
  • 19 Hansson G K, Libby P. The immune response in atherosclerosis: a double-edged sword.  Nat Rev Immunol. 2006;  6 508-519
    CrossrefPubMedGoogle Scholar
  • 20 Apple F S, Wu A H, Mair J. et al . Future biomarkers for detection of ischemia and risk stratification in acute coronary syndrome.  Clin Chem. 2005;  51 810-824
    CrossrefPubMedGoogle Scholar
  • 21 Cybulsky M I, Iiyama K, Li H. et al . A major role for VCAM-1, but not ICAM-1, in early atherosclerosis.  J Clin Invest. 2001;  107 1255-1262
    CrossrefPubMedGoogle Scholar
  • 22 Amorino G P, Hoover R L. Interactions of monocytic cells with human endothelial cells stimulate monocytic metalloproteinase production.  Am J Pathol. 1998;  152 199-207
    PubMedGoogle Scholar
  • 23 Moulton K S, Vakili K, Zurakowski D. et al . Inhibition of plaque neovascularization reduces macrophage accumulation and progression of advanced atherosclerosis.  Proc Natl Acad Sci USA. 2003;  100 4736-4741
    CrossrefPubMedGoogle Scholar
  • 24 Croce K, Libby P. Intertwining of thrombosis and inflammation in atherosclerosis.  Curr Opin Hematol. 2007;  14 55-61
    CrossrefPubMedGoogle Scholar
  • 25 Amento E P, Ehsani N, Palmer H, Libby P. Cytokines and growth factors positively and negatively regulate interstitial collagen gene expression in human vascular smooth muscle cells.  Arterioscler Thromb. 1991;  11 1223-1230
    PubMedGoogle Scholar
  • 26 Naruko T, Ueda M, Haze K. et al . Neutrophil Infiltration of Culprit Lesions in Acute Coronary Syndrome.  Circulation. 2002;  106 2894-2900
    CrossrefPubMedGoogle Scholar
  • 27 Sugiyama S, Okada Y, Sukhova G K. et al . Macrophage myeloperoxidase regulation by granulocyte macrophage colony-stimulating factor in human atherosclerosis and implications in acute coronary syndromes.  Am J Pathol. 2001;  158 879-891
    PubMedGoogle Scholar
  • 28 Fu X, Kassim S Y, Parks W C, Heinecke J W. Hypochlorous acid generated by myeloperoxidase modifies adjacent tryptophan and glycine residues in the catalytic domain of matrix metalloproteinase-7 (matrilysin): an oxidative mechanism for restraining proteolytic activity during inflammation.  J Biol Chem. 2003;  278 28 403-28 409
    PubMedGoogle Scholar
  • 29 Wang Y, Rosen H, Madtes D K. et al . Myeloperoxidase inactivates TIMP-1 by oxidizing its N-terminal cysteine residue: an oxidative mechanism for regulating proteolysis during inflammation.  J Biol Chem. 2007;  282 31826-31834
    CrossrefPubMedGoogle Scholar
  • 30 Spiel A O, Gilbert J C, Jilma B. von Willebrand factor in cardiovascular disease: focus on acute coronary syndromes.  Circulation. 2008;  117 1449-1459
    CrossrefPubMedGoogle Scholar
  • 31 Ray K K, Morrow D A, Gibson C M. et al . Predictors of the rise in vWF after ST elevation myocardial infarction: implications for treatment strategies and clinical outcome: An ENTIRE-TIMI 23 substudy.  Eur Heart J. 2005;  26 440-446
    PubMedGoogle Scholar
  • 32 Montalescot G, Philippe F, Ankri A. et al . Early increase of von Willebrand factor predicts adverse outcome in unstable coronary artery disease: beneficial effects of enoxaparin. French Investigators of the ESSENCE Trial.  Circulation. 1998;  98 294-299
    PubMedGoogle Scholar
  • 33 Eiserich J P, Baldus S, Brennan M L. et al . Myeloperoxidase, a leukocyte-derived vascular NO oxidase.  Science. 2002;  296 2391-2394
    CrossrefPubMedGoogle Scholar
  • 34 Goldmann B U, Rudolph V, Rudolph T K. et al . Neutrophil activation precedes myocardial injury in patients with acute myocardial infarction.  Free Radic Biol Med. 2009;  Epub ahead of print
    PubMedGoogle Scholar
  • 35 Brennan M L, Penn M S, Van Lente F. et al . Prognostic value of myeloperoxidase in patients with chest pain.  N Engl J Med. 2003;  349 1595-1604
    CrossrefPubMedGoogle Scholar
  • 36 Baldus S, Heeschen C, Meinertz T. et al . Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes.  Circulation. 2003;  108 1440-1445
    CrossrefPubMedGoogle Scholar
  • 37 Tang W H, Brennan M L, Philip K. et al . Plasma myeloperoxidase levels in patients with chronic heart failure.  Am J Cardiol. 2006;  98 796-799
    CrossrefPubMedGoogle Scholar
  • 38 Exner M, Minar E, Mlekusch W. et al . Myeloperoxidase predicts progression of carotid stenosis in states of low high-density lipoprotein cholesterol.  J Am Coll Cardiol. 2006;  47 2212-2218
    CrossrefPubMedGoogle Scholar
  • 39 André P, Nannizzi-Alaimo L, Prasad S K, Phillips D R. Platelet-derived CD40L: the switch-hitting player of cardiovascular disease.  Circulation. 2002;  106 896-899
    CrossrefPubMedGoogle Scholar
  • 40 Varo N, de Lemos J A, Libby P. et al . Soluble CD40L: risk prediction after acute coronary syndromes.  Circulation. 2003;  108 1049-1052
    CrossrefPubMedGoogle Scholar
  • 41 Heeschen C, Dimmeler S, Hamm C W. et al . Pregnancy-associated plasma protein-A levels in patients with acute coronary syndromes: comparison with markers of systemic inflammation, platelet activation, and myocardial necrosis.  J Am Coll Cardiol. 2005;  45 229-237
    CrossrefPubMedGoogle Scholar
  • 42 Morrow D A, Sabatine M S, Brennan M L. et al . Concurrent evaluation of novel cardiac biomarkers in acute coronary syndrome: myeloperoxidase and soluble CD40 ligand and the risk of recurrent ischaemic events in TACTICS-TIMI 18.  Eur Heart J. 2008;  29 1096-1102
    CrossrefPubMedGoogle Scholar
  • 43 Olenchock B A, Wiviott S D, Murphy S A. et al . Lack of association between soluble CD40L and risk in a large cohort of patients with acute coronary syndrome in OPUS TIMI-16.  J Thromb Thrombolysis. 2008;  26 79-84
    CrossrefPubMedGoogle Scholar
  • 44 Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry.  Circ Res. 2003;  92 827-839
    CrossrefPubMedGoogle Scholar
  • 45 Blankenberg S, Rupprecht H J, Poirier O. et al . Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease.  Circulation. 2003;  107 1579-1585
    CrossrefPubMedGoogle Scholar
  • 46 Hessian P A, Edgeworth J, Hogg N. MRP-8 and MRP-14, two abundant Ca(2+)-binding proteins of neutrophils and monocytes.  J Leukoc Biol. 1993;  53 197-204
    PubMedGoogle Scholar
  • 47 Morrow D A, Wang Y, Croce K. et al . Myeloid-related protein 8 / 14 and the risk of cardiovascular death or myocardial infarction after an acute coronary syndrome in the Pravastatin or Atorvastatin Evaluation and Infection Therapy: Thrombolysis in Myocardial Infarction (PROVE IT-TIMI 22) trial.  Am Heart J. 2008;  155 49-55
    CrossrefPubMedGoogle Scholar
  • 48 Healy A M, Pickard M D, Pradhan A D. et al . Platelet expression profiling and clinical validation of myeloid-related protein-14 as a novel determinant of cardiovascular events.  Circulation. 2006;  113 2278-2284
    CrossrefPubMedGoogle Scholar
  • 49 Lund J, Qin Q P, Ilva T. et al . Circulating pregnancy-associated plasma protein a predicts outcome in patients with acute coronary syndrome but no troponin I elevation.  Circulation. 2003;  108 1924-1926
    CrossrefPubMedGoogle Scholar
  • 50 Qin Q P, Laitinen P, Majamaa-Voltti K. et al . Release patterns of pregnancy associated plasma protein A (PAPP-A) in patients with acute coronary syndromes.  Scand Cardiovasc J. 2002;  36 358-361
    CrossrefPubMedGoogle Scholar
  • 51 Iyer S, Acharya K R. Role of placenta growth factor in cardiovascular health.  Trends Cardiovasc Med. 2002;  12 128-134
    CrossrefPubMedGoogle Scholar
  • 52 Hattori K, Heissig B, Wu Y. et al . Placental growth factor reconstitutes hematopoiesis by recruiting VEGFR1(+) stem cells from bone-marrow microenvironment.  Nat Med. 2002;  8 841-849
    PubMedGoogle Scholar
  • 53 Heeschen C, Dimmeler S, Fichtlscherer S. et al . Prognostic value of placental growth factor in patients with acute chest pain.  JAMA. 2004;  291 435-441
    CrossrefPubMedGoogle Scholar

Dr. med. Tanja K. Rudolph

Klinik für Allgemeine und Interventionelle Kardiologie
Universitäres Herzzentrum Hamburg
Universitätsklinikum Hamburg-Eppendorf

Martinistr. 52
20246 Hamburg

Email: t.rudolph@uke.de

      >